INMUNE BIO INC. Employee Benefits and Share-based Compensation
INMUNE BIO INC. (INMB) reported Employee Benefits and Share-based Compensation of $1.30 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs
us-gaap:EmployeeBenefitsAndShareBasedCompensation · last filed 2026-03-30
- INMUNE BIO INC. employee benefits and share-based compensation for the quarter ending 2023-12-31 was -$4.36M.
- INMUNE BIO INC. employee benefits and share-based compensation for the quarter ending 2023-09-30 was $1.90M, a 0.00% change year-over-year.
- INMUNE BIO INC. employee benefits and share-based compensation for the quarter ending 2023-06-30 was $1.90M, a 0.00% change year-over-year.
- INMUNE BIO INC. employee benefits and share-based compensation for the quarter ending 2022-12-31 was -$4.35M.
- INMUNE BIO INC. employee benefits and share-based compensation for fiscal 2024 was $1.30M, a 13.47% increase from fiscal 2023.
- INMUNE BIO INC. employee benefits and share-based compensation for fiscal 2023 was $1.14M, a 8.96% increase from fiscal 2022.
- INMUNE BIO INC. employee benefits and share-based compensation for fiscal 2022 was $1.05M, a 9.26% decline from fiscal 2021.
- INMUNE BIO INC. employee benefits and share-based compensation for fiscal 2021 was $1.16M, a 92.99% increase from fiscal 2020.
| Period end | Employee Benefits and Share-based Compensation 3 month | Employee Benefits and Share-based Compensation 6 month | Employee Benefits and Share-based Compensation 9 month | Employee Benefits and Share-based Compensation 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.30M 10-K · filed 2026-03-30 | |||
| 2023-12-31 | -$4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$2.46M derived: sum of 2 quarters · filed 2025-03-27 | -$557.00K derived: sum of 3 quarters · filed 2025-03-27 | $1.14M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.90M 10-Q · filed 2023-11-01 | $3.80M derived: sum of 2 quarters · filed 2023-11-01 | $5.50M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $1.90M 10-Q · filed 2023-08-07 | $3.60M 10-Q · filed 2023-08-07 | ||
| 2022-12-31 | -$4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$2.45M derived: sum of 2 quarters · filed 2024-03-28 | -$551.00K derived: sum of 3 quarters · filed 2024-03-28 | $1.05M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.90M 10-Q · filed 2023-11-01 | $3.80M derived: sum of 2 quarters · filed 2023-11-01 | $5.40M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $1.90M 10-Q · filed 2023-08-07 | $3.40M 10-Q · filed 2023-08-07 | ||
| 2021-12-31 | $1.16M 10-K · filed 2023-03-02 | |||
| 2020-12-31 | $599.00K 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |